Inside The ANDA Parking Lot
Executive Summary
A firm will take ownership of US ANDAs from manufacturers unwilling to pay program fees or withdraw the approved generic drug application; is it a novel concept allowing future marketing options or simply fee avoidance?
You may also be interested in...
Generic Application Mystery: Few ANDAs Withdrawn To Start FY 2023
In past years, sponsors have pulled ANDAs at the beginning of a fiscal year in part to control their GDUFA program fee payments, but no approved ANDAs were withdrawn during the first two months of FY 2023.
FDA Reports Millions In Unpaid GDUFA Fees
The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.
US FDA Reports Millions In Unpaid GDUFA Program Fees
The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.